Lysando Welcomes Healthcare Visionary Jorge Cortell to its Advisory Board

2023-09-07
·
交易
高管变更
TRIESENBERG, Liechtenstein--(BUSINESS WIRE)-- Lysando, leading biotech in antimicrobial proteins, proudly announces the addition of Mr. Jorge Cortell to its esteemed Advisory Board marking a significant milestone in the company's growth. As a serial entrepreneur and renowned visionary in healthcare technology he brings a wealth of expertise to Lysando's strategic direction. This press release features multimedia. View the full release here: Jorge Cortell - Advisory Board Member Lysando AG As Senior Advisor for Healthcare and Life Sciences at Harvard University Innovation Laboratories, and a technology advisor to NLC, Europe's largest HealthTech Venture Builder, Jorge Cortell's background positions him as a thought leader in the global industry. His profound understanding of both tech and business landscapes makes him an asset in guiding Lysando towards new heights of success. “At Lysando, our mission is helping patients rather than simply selling treatments. Antibiotic resistance is estimated to claim over a million lives annually worldwide, posing an existential threat to society. Moreover, contamination of our environment by pharmaceuticals, particularly antibiotics, poses an alarming additional danger,” says Count Markus Matuschka de Greiffenclau, Chairman of the Board of Directors of Lysando AG. “With our Artilysin® technology, we are committed to combating resistance, promoting green pharma practices, and envisioning a future without fear of bacterial infections. As time is of the essence, we are delighted to have Jorge on board; a visionary who embodies innovation, comprehends AI, and supports Lysando's endeavour to save millions from pathogenic bacteria.” “I am delighted to announce my appointment to the Advisory Board of this pioneer in the field of innovative antimicrobial solutions,” says Jorge Cortell, newly appointed Advisory Board member of Lysando AG. “Joining Lysando represents an exciting opportunity to contribute my expertise in cutting-edge technologies and their potential to revolutionize healthcare. I believe in Lysando's mission to address the global challenge of antimicrobial resistance and to improve patient outcomes through transformative therapeutic solutions. Together, we will strive to shape a healthier future by harnessing the power of science and innovation.” Jorge Cortell's involvement on the Advisory Board promises to drive the company's mission, ultimately ushering in a future of improved quality of life for all. About Lysando AG Lysando is market leader for antimicrobial proteins, so‐called Artilysin® molecules. They can effectively eliminate problem‐causing bacteria without associated high risk of resistance formation and microbial disbalances. Artilysin® constitutes an innovative, proprietary, and environmentally friendly technology with a wide range of applications. View source version on businesswire.com: Contacts Verena Schossmann +41(0)79 211 83 42 Verena.Schossmann@lysando.com Source: Lysando Smart Multimedia Gallery Photo Jorge Cortell - Advisory Board Member Lysando AG Logo View this news release and multimedia online at:
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
靶点
-
药物
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。